GS
BBIO icon

GTS Securities’s BridgeBio Pharma BBIO Stock Holding History

GTS Securities’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$256K Buy
+3,446
New +$250K 0.01% 1199
2025
Q4 		– Sell
-5,632
Closed -$293K – 1395
2025
Q3 		$293K Buy
+5,632
New +$275K 0.01% 1053

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GTS Securities's BBIO Position: Q1 2026 in Review

GTS Securities opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 3,446 shares worth $256K. The stake represents 0.01% of the portfolio and ranks #1199 among its holdings. This is a return to the name: GTS Securities previously reported a position in BBIO as recently as Q3 2025.

GTS Securities first reported a position in BBIO in Q3 2025 and has held it in 2 quarters since. The position peaked at $293K in Q3 2025. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • GTS Securities held 3,446 shares of BridgeBio Pharma worth $256K as of Q1 2026.
  • BridgeBio Pharma was a new GTS Securities position in Q1 2026.
  • BridgeBio Pharma made up 0.01% of GTS Securities's portfolio in Q1 2026, its #1199 holding.
  • GTS Securities first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 2 quarters since.
  • GTS Securities's BridgeBio Pharma position peaked at $293K in Q3 2025.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.